MNM Bioscience Inc.
MNM Bioscience applies AI-driven analysis of whole-genome and multi-omics data to predict cancer patient responses and identify novel drug targets. The company combines machine learning, bioinformatics pipelines, distributed cloud computation, and a proprietary biobank of clinical genomes to derive predictive and stratification algorithms for therapies such as CDK4/6 inhibitors, HRD, and PD‑1 blockade. MNM operates as a B2B SaaS and drug-discovery platform, offering analytical tools to clinicians and partners while pursuing internal therapeutics (e.g., MNM177). Its stack centers on next-generation sequencing, multi-omics integration, and custom ML models deployed via cloud infrastructure to support precision oncology and target nomination. MNM addresses the needs of clinical genomics and pharmaceutical development markets by translating patient-derived mutation patterns into actionable biomarkers and candidate targets.
MNM Bioscience Inc.
MNM Bioscience applies AI-driven analysis of whole-genome and multi-omics data to predict cancer patient responses and identify novel drug targets. The company combines machine learning, bioinformatics pipelines, distributed cloud computation, and a proprietary biobank of clinical genomes to derive predictive and stratification algorithms for therapies such as CDK4/6 inhibitors, HRD, and PD‑1 blockade. MNM operates as a B2B SaaS and drug-discovery platform, offering analytical tools to clinicians and partners while pursuing internal therapeutics (e.g., MNM177). Its stack centers on next-generation sequencing, multi-omics integration, and custom ML models deployed via cloud infrastructure to support precision oncology and target nomination. MNM addresses the needs of clinical genomics and pharmaceutical development markets by translating patient-derived mutation patterns into actionable biomarkers and candidate targets.
TL;DR
Focus: AI-driven analysis of whole-genome and multi-omics data for cancer response prediction and target nomination
Business model: B2B SaaS and drug-discovery platform with internal therapeutics pipeline
Founded: 2018
Headquarters: Cambridge, Massachusetts
Total funding (public record): USD 3,291,141 (multiple seed rounds; last 2020-10-20)
Company Overview
Problem Domain
Precision oncology: improving therapy response prediction and target identification from clinical genomics data.
Founded
2018
Industry
Biotechnology
Tech Stack
Funding Track Record
USD 3,291,141
Multiple seed rounds reported; investors listed include RTA.vc and Black Pearls VC; company listed as closed in some public profiles.
Investor Signal
“Investors include RTA.vc (lead) and Black Pearls VC”